[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"plasmodium-falciparum-malaria\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:plasmodium-falciparum-malaria":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,82],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100650556","assessing-vaccine-effectiveness-of-r21matrix-m-across-malaria-transmission-settings-avert-100650556",false,"NCT07749911","Assessing Vaccine Effectiveness of R21\u002FMatrix-M Across Malaria Transmission Settings (AVERT)","Real-World Effectiveness of the R21\u002FMatrix-M Malaria Vaccine in Children in Burkina Faso and Uganda","AVERT","Inclusion Criteria:\n\n* Residence in an area where R21\u002FMatrix-M is implemented and within the catchment area of a selected study facility.\n* Younger than 5 years and eligibleto receive R21\u002FMatrix-M under the national vaccination schedule at rollout.\n* Meets the country definition of suspected malaria, generally axillary temperature of at least 37.5 degrees Celsius or a history of fever within the previous 24 hours, and is undergoing malaria testing.\n* Written informed consent provided by an adult caregiver aged 18 years or older.\n\nExclusion Criteria:\n\n* Caregiver is unable or unwilling to provide informed consent.\n* Severe non-malaria illness at presentation that would interfere with study participation.\n* Repeat presentation within the protocol-defined exclusion window after a previous enrollment: within 14 days after a microscopy-positive visit; or more than 7 but fewer than 14 days after a microscopy-negative visit. A microscopy-negative visit followed by a positive diagnosis within 7 days will be reclassified as positive rather than treated as a new enrollment.\n* Documented receipt of any RTS,S malaria vaccine dose.","ALL","5 Months","5 Years",{"count":21,"type":22},20000,"ESTIMATED","OBSERVATIONAL","The AVERT study is a prospective observational test-negative case control study evaluating the real-world effectiveness of the R21\u002FMatrix-M malaria vaccine among children younger than 5 years in Burkina Faso and Uganda. Children who seek outpatient care with suspected malaria and are eligible for the national R21\u002FMatrix-M vaccination program will be enrolled. Malaria infection will be determined by blood smear microscopy. Children with a positive microscopy result will be classified as cases and children with a negative result as controls. Vaccination history, including the number and timing of doses, will be obtained primarily from vaccination cards or other written records. Vaccine effectiveness will be estimated by comparing the odds of vaccination among cases and controls.",[26,27],"Malaria","PLASMODIUM FALCIPARUM MALARIA",[29,30,31,32,33,34,35,36],"R21\u002FMatrix-M","Malaria vaccine","Vaccine effectiveness","Test-negative design","Clinical malaria","Children","Burkina Faso","Uganda","RECRUITING","2026-08-03",{"date":40,"type":41},"2026-08-06","ACTUAL",{"date":43,"type":41},"2026-07-14",{"date":45,"type":22},"2027-08",{"name":47,"class":48},"Clinton Health Access Initiative Inc.","OTHER",21,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":17,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":70,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100607908","phase-4-r21mm-dosing-presentations-and-preservatives-100607908","NCT07194668","R21\u002FMM Dosing, Presentations, and Preservatives","Immunogenicity of a Fractional Adult Dose of the Malaria Vaccine R21\u002FMatrix-M - A Noninferiority Trial","VAC100","Inclusion Criteria:\n\n* Residence in a study village for the study period, i.e. 12 months.\n* Age 14 years to 60 years.\n* Written informed consent\u002Fassent provided by participants (or a parent\u002Fguardian in case the participant is under 18 years old).\n\nExclusion Criteria:\n\n* Pregnancy, plan to get pregnant within one month of vaccination, or breastfeeding.\n* Acute illness requiring intervention.\n* A history of an adverse reaction to study vaccine.\n* Prior receipt of any other malaria vaccine.\n* Enrolment in another intervention trial in the last month.\n* Planned enrolment in another intervention trial in the coming 12 months.\n* Regular use of Immunomodulating drugs e.g, Steroid, Methotrexate, Immunotherapy etc. in the past month and\u002For planned for the coming 12 months.",true,"14 Years","60 Years",{"count":62,"type":22},375,"INTERVENTIONAL",[65],"PHASE4","This is a single blind randomised controlled trial (Phase 3 trial). This study aims to assess whether a half-dose of the R21\u002FMatrix-M malaria vaccine is as effective as the full dose in children and adults. The results will help optimize vaccine usage and improve malaria prevention strategies.\n\nAll participants will receive the same number of injections and will be randomly assigned to receive one of the followings:\n\n* Group 1: Adults and adolescents receiving the standard adult vaccine dose: 10μg R21\u002F50μg Matrix-M (n=125).\n* Group 2: Adults and adolescents receiving a half of the standard adult vaccine dose: 5μg R21\u002F50μg Matrix-M: 10 dose vials with adaptor Preservative Free (n=125)\n* Group 3: Adults and adolescents receiving a half of the standard adult vaccine dose: 5μg R21\u002F50μg Matrix-M: 10 dose vials with 2PE Preservative (n=125)\n\nClinical procedure for participants:\n\n* Standardized symptom questionnaire\n* Physical examination:\n\nWeight, height, pulse, blood pressure, respiratory rate, tympanic temperature. Spleen and liver size will be recorded if palpable. Pregnancy test (for female of child bearing potential)\n\n* Venous blood collection (Pre-vaccination) 3mL\n* Vaccination",[68,26,69],"Plasmodium Falciparum Malaria","Vaccine Reaction",[68,71],"Malaria Vaccine","NOT_YET_RECRUITING",{"date":74,"type":41},"2026-08-04",{"date":76,"type":22},"2026-08-15",{"date":78,"type":22},"2026-12-31",{"name":80,"class":48},"University of Oxford",2,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":90,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":63,"phases":93,"briefSummary":94,"conditions":95,"keywords":96,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":81},"100521356","phase-4-mass-vaccine-and-drug-administration-bangladesh-100521356","NCT06068530","Mass Vaccine and Drug Administration, Bangladesh","A Cluster-randomised, Open-label Trial to Compare the Impact of Combined Mass Vaccine and Drug Administrations, Mass Drug Administration, Mass Vaccinations, or no Intervention on Plasmodium Falciparum Malaria Transmission","MVDA","Inclusion Criteria:\n\n* Current residence in a study village irrespective of permanence\n* Age 6 months and above (no upper age limit)\n* Written informed consent provided by participants (or a parent\u002Fguardian in case the participant is under 18 years old)\n\nExclusion Criteria:\n\n* Pregnancy, plan to get pregnant, or breastfeeding.\n* Acute illness requiring intervention\n* A history of an adverse reaction to study drugs\u002Fvaccine and prior receipt of any other malaria vaccine or enrolment in another intervention trial.","6 Months",{"count":92,"type":22},10000,[65],"This is an open i.e. not blinded, cluster-randomised, controlled intervention study. The study will use a factorial design to estimate the protective effectiveness of mass drug administrations, mass vaccinations, combined mass vaccinations and drug administrations versus the current standard of care.",[68],[68,71,97],"Malaria Drug Administrations","2025-12-11",{"date":100,"type":41},"2025-12-18",{"date":102,"type":41},"2025-02-15",{"date":104,"type":22},"2028-02-01",{"name":80,"class":48}]